---
title: Improve walking balance via aquatherapy
nct_id: NCT07390825
phase: NA
status: RECRUITING
sponsor: Ankara City Hospital Bilkent
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07390825"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07390825"
last_fetched: "2026-05-10T14:01:53.316Z"
source: "Parkinson's Pathways (curated)"
---
# Improve walking balance via aquatherapy

**Goal (in five words):** Improve walking balance via aquatherapy

**Official Title:** Evaluation of the Effects of Aquatic Therapy on Activities of Daily Living, Walking, Balance, Posture, Pain, and Depression in Parkinson's Patients

**Trial ID:** [NCT07390825](https://clinicaltrials.gov/study/NCT07390825)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Ankara City Hospital Bilkent
- **Target Enrollment:** 42 participants
- **Start Date:** 2025-01-01
- **Completion Date:** 2026-08-01
- **Conditions:** Parkinson Disease
- **Interventions:** Aquatherapy, home exercise
- **Intervention Types:** OTHER

## Summary For Families

The goal is to see whether regular aquatic therapy can improve daily activities, walking, balance, posture, pain, and depression in people with mild to moderate Parkinson's. Participants get supervised aquatic therapy in warm water, where buoyancy reduces joint load and fall risk, gentle water resistance helps strengthen muscles and practice gait and balance, and the soothing environment can ease pain and lift mood; this is a physical therapy approach that complements, and does not interact with, usual medications like levodopa. The trial is looking for adults 40 to 80 with idiopathic Parkinson's at Hoehn and Yahr stages 1 to 3, on a stable medication plan for at least 3 months, cognitively able (MMSE 24+), and able to stand and walk with or without assistance.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Having a diagnosis of Idiopathic Parkinson's Disease between the ages of 40-80 and consenting to the treatment.
* Being regularly followed by a neurologist and having a stable medical treatment regimen for at least 3 months.
* Having a disease stage between 1-3 according to the Modified Hoehn-Yahr Staging Scale (MHY).
* A score of 24 or higher on the Mini-Mental State Examination (MMSE).
* Being able to verticalize independently and ambulate with or without assistance.

Exclusion Criteria:

* Having orthopedic, rheumatological, or non-Parkinson's neurological disorders that affect functional status.
* Having a medical treatment regimen that has been modified within the last 3 months.
* Presence of Atypical Parkinson's Disease.
* Visual impairment.
* Presence of dementia.
* Decompensated cardiac or respiratory failure.
* Diabetes insipidus.
* Presence of systemic infection.
* Impaired skin integrity or the presence of skin infections.
* Increased sensitivity to inhaled steam or water chemicals.
* History of epilepsy or asthma.
* Urinary or fecal incontinence.
* Refusal to participate in or consent to the treatment.
```

## Locations (2)

- Bilkent City Hospital, Çankaya, Ankara, Turkey (Türkiye) _(39.9179, 32.8627)_
  - Duygu Yanıktaş, MD — (CONTACT) — 05059025460 — yanktasduygu@gmail.com
  - Duygu Yanıktaş, MD — (PRINCIPAL_INVESTIGATOR)
  - Halil Uçan, MD — (PRINCIPAL_INVESTIGATOR)
  - Ebru Bilge Dirik, MD — (SUB_INVESTIGATOR)
  - Şeyma Cebe Karaca — (SUB_INVESTIGATOR)
- Bilkent City Hospital, Ankara, ÇANKAYA, Turkey (Türkiye) _(39.9199, 32.8543)_

## Central Contacts

- Duygu Yanıktaş, MD — (CONTACT) — +905059025460 — yanktasduygu@gmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07390825*  
*HTML version: https://parkinsonspathways.com/trial/NCT07390825*  
*Source data: https://clinicaltrials.gov/study/NCT07390825*